CoChat

Effects of Eligibility Criteria on Patient Selection and Treatment Implications from 10 Multidomain Dementia Prevention Trials: A Population-Based Study

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Introduction: Dementia prevention trials have so far shown little benefit of multidomain interventions against cognitive decline. Recruitment strategies in these trials often centre around dementia risk or cardiovascular risk profile, but it is uncertain whether this leads to inclusion of individuals who may benefit most from the intervention. We determined the effects of eligibility criteria on the recruitment of potential trial participants in the general population. Methods: In a systematic search until January 1, 2022, we identified all published and ongoing large (≥500 participants), phase-3 multidomain trials for the prevention of cognitive decline or dementia. We applied trial eligibility criteria to 5,381 participants of the population-based Rotterdam Study (mean age: 72 years, 58% women), to compare participant characteristics, predicted risk of cardiovascular disease, and dementia risk, between trial eligible and ineligible persons. Results: We identified 10 trials, of which 5 had been published (DR’s EXTRA, FINGER, preDIVA, MAPT, and HATICE) and 5 are ongoing (US-POINTER, MIND-CHINA, MYB, AgeWell.de, and J-Mint). Among all Rotterdam Study participants, eligibility across published trials ranged from 48% for MAPT to 87% for preDIVA, in line with original trial reports. Variability in eligibility was wider for ongoing trials, from 1% for US-POINTER to over 94% for MYB trial. Over 70% of trial eligible individuals are recommended preventive intervention in routine care based on their cardiovascular risk, similar for lipid-lowering (71%) and blood pressure-lowering treatment (73%). Ten-year risks of dementia were similar for eligible compared to ineligible individuals (12 vs. 11%). Conclusion: Multidomain dementia prevention trials fail to preferentially include those at the highest risk of dementia and mostly include individuals who qualify for interventions already on the basis of cardiovascular prevention guidelines. These findings call for better targeted enrolment of individuals for whom trial results can improve clinical decision-making.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000528120

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Overlap in trial eligibility across published trials. Of all 5,381 participants in the Rotterdam Study cohort, 1,028 (17.7%) were not eligible for any of the trials, whereas only 127 individuals (2.2%) were eligible for all five trials. Each dot represents a mutually exclusive category. For example, 525 individuals were eligible only for HATICE. The FINGER and DR's EXTRA trials had the largest overlap in trial eligibility.
Fig. 1 Overlap in trial eligibility across published trials. Of all 5,381 participants in the Rotterdam Study cohort, 1,028 (17.7%) were not eligible for any of the trials, whereas only 127 individuals (2.2%) were eligible for all five trials. Each dot represents a mutually exclusive category. For example, 525 individuals were eligible only for HATICE. The FINGER and DR's EXTRA trials had the largest overlap in trial eligibility.CC BY-NC · PubMed Central
Fig. 2 Proportion of people in the general population who qualify for lipid-lowering treatment according to European guidelines for cardiovascular risk management, stratified by trial eligibility (panel a: eligible persons and panel b: ineligible persons). Dashed lines represent overall means of recommended cardiovascular preventive treatment.
Fig. 2 Proportion of people in the general population who qualify for lipid-lowering treatment according to European guidelines for cardiovascular risk management, stratified by trial eligibility (panel a: eligible persons and panel b: ineligible persons). Dashed lines represent overall means of recommended cardiovascular preventive treatment.CC BY-NC · PubMed Central
Fig. 3 Proportion of people in the general population who qualify for blood pressure-lowering treatment according to European guidelines for cardiovascular risk management, stratified by trial eligibility (panel a: eligible persons and panel b: ineligible persons). Dashed lines represent overall means of recommended cardiovascular preventive treatment.
Fig. 3 Proportion of people in the general population who qualify for blood pressure-lowering treatment according to European guidelines for cardiovascular risk management, stratified by trial eligibility (panel a: eligible persons and panel b: ineligible persons). Dashed lines represent overall means of recommended cardiovascular preventive treatment.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 14

Metadata

Authors
Licher, S., Wolters, F. J., Pavlović, J., Kavousi, M., Leening, M. J. G., Ikram, M. K., & Ikram, M. A.
Affiliations
Erasmus MC (NL)
Corresponding author
Licher, Silvan
Venue
Neuroepidemiology
Publisher
S. Karger AG
Published
2022-11-17
Volume
57
Issue
1
Pages
14-24
ISSN
  • 0251-5350 (ISSN-L)
  • 1423-0208
OpenAlex
W4309263713
Cited by
13
References
32
Citations by year
2026: 5 · 2025: 4 · 2024: 3 · 2023: 1
FWCI
1.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuroepidemiology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Cognitive Abilities and Testing
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
Keywords
dementia prevention, eligibility criteria, trial recruitment, multidomain intervention, cognitive decline, cardiovascular risk, dementia risk, Rotterdam Study, cardiovascular prevention guidelines, lipid-lowering therapy, blood pressure-lowering treatment
MeSH terms
Aged, Cardiovascular Diseases, Dementia, Female, Humans, Male, Research Design, Patient Selection, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.